SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Blueprint Medicines Corporation (BPMC) , 前瞻盈利收益率 0.71%. PEG 1.31.
本頁證實的標準:
- VALUE (60/100, 通過) — 綜合估值評分超過60/100的通過門檻。
- 前瞻本益比 141.0
- PEG 比率 1.31 — 介於1.0–2.0之間，表明相對於成長的估值適中。
- 分析師共識目標價 $141.00 (+8.9% 上行空間) — 預期溫和上漲。
SharesGrow 綜合評分： 46/100 其中 3/7 項標準通過。
SharesGrow 7-Criteria Score
✓
價值
60/100
Price-to-Earnings & upside
Proven by this page
✗
健康
33/100
Debt-to-Equity & liquidity
→ Health
估值概覽 — BPMC
估值倍數
P/E (TTM)0.0
前瞻 P/E141.0
PEG 比率1.31
前瞻 PEG1.31
P/B 比率0.00
P/S 比率15.99
EV/EBITDA0.0
每股數據
EPS (TTM)$-1.07
前瞻 EPS（預估）$0.92
每股帳面價值$0.00
每股營收$8.09
每股自由現金流$0.00
收益率與內在價值
盈利收益率N/A
Forward Earnings Yield0.71%
股息收益率0.00%
分析師目標價$141.00 (+8.9%)
P/E Ratio & Earnings Yield
每股盈餘 (EPS) 歷史
| Year |
EPS（稀釋） |
營收 |
淨利潤 |
淨利潤率 |
| 2015 |
$-2.89 |
$11.4M |
$-52.77M |
-462.9% |
| 2016 |
$-2.64 |
$27.77M |
$-72.5M |
-261% |
| 2017 |
$-3.92 |
$21.43M |
$-148.12M |
-691.3% |
| 2018 |
$-5.39 |
$44.52M |
$-236.64M |
-531.5% |
| 2019 |
$-6.87 |
$66.51M |
$-328.7M |
-494.2% |
| 2020 |
$5.59 |
$793.74M |
$313.88M |
39.5% |
| 2021 |
$-11.01 |
$180.08M |
$-644.09M |
-357.7% |
| 2022 |
$-9.35 |
$204.04M |
$-557.52M |
-273.2% |
| 2023 |
$-8.37 |
$249.38M |
$-506.98M |
-203.3% |
| 2024 |
$-1.07 |
$508.82M |
$-67.09M |
-13.2% |
